Davita Inc - DVA STOCK NEWS

DaVita Inc. (NYSE: DVA) has announced the upsize of its private offering of senior notes from $750 million to $1 billion. These 4.625% notes are due on June 1, 2030 and will be issued at an offering price of 101.750%. The closing of the offering is expected on February 26, 2021. Proceeds will be used to pay down $550 million in revolving credit, cover offering expenses, and support general corporate purposes. The offering is targeted at qualified institutional buyers under Regulation S.

DaVita Inc. (NYSE: DVA) has initiated a private offering of $750 million in additional 4.625% senior notes, maturing on June 1, 2030. These notes will be issued under an existing indenture and will share the same terms as previously issued notes of $1.75 billion. Proceeds will be used to reduce borrowings, cover offering expenses, and for general corporate purposes, including potential stock repurchases. This issuance is targeting qualified institutional buyers and is subject to regulatory compliance.

DaVita reported financial results for Q4 and full-year 2020, with diluted EPS from continuing operations at $6.39, a 38.9% increase year-over-year. Q4 diluted EPS was $1.67, impacted by COVID-19 with a $60 million operating income loss. Total revenues were $2.905 billion for Q4 and $11.551 billion for the year. Operating cash flow was $485 million in Q4, and free cash flow was $210 million. The company served approximately 240,400 patients across 3,137 centers, opening 14 new centers in Q4.

DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on February 11, 2021, at 5:00 p.m. Eastern Time, to discuss fourth quarter results. The results will be released after market close on the same day. This call will be webcast, accessible through the DaVita IR web page. The dial-in number for participants is 877-918-6630, with an international option at 517-308-9042. A replay will be available on DaVita's website after the call. DaVita is a leading provider of kidney care services in the U.S., committed to improving patient care.

DaVita announced that its annual cycling event, Tour DaVita, raised nearly $1 million for Bridge of Life, a nonprofit focused on global health care. This year's event was adapted to a virtual format due to COVID-19, attracting almost 3,600 participants who logged over 45,000 miles in various activities. Bridge of Life will utilize these funds to enhance health care services, especially to combat COVID-19 in 13 countries. DaVita operates over 2,800 outpatient dialysis centers in the U.S. as of September 2020, emphasizing its commitment to innovative kidney care.

DaVita Kidney Care has expressed gratitude following the defeat of Proposition 23 in California, which could have threatened access to dialysis for over 80,000 patients. The company criticized the SEIU-UHW labor union for its opposition to the dialysis community and reaffirmed its commitment to prioritizing patient health and safety. DaVita is a leading provider of kidney care services in the U.S., serving 205,300 patients at 2,809 centers nationwide as of September 30, 2020, and has been a pioneer in clinical quality and innovation in kidney care.

DaVita Inc. (NYSE: DVA) reported solid financial results for Q3 2020, with consolidated revenues of $2.924 billion and operating income of $438 million, achieving a 15.0% operating margin. Diluted earnings per share from continuing operations rose to $1.28, up from $0.99 in Q3 2019. The company repurchased over 8 million shares at an average cost of $88.13 and maintained strong cash flows, generating $483 million in operating cash flow. However, advocacy costs surged to $66 million due to efforts against union initiatives, impacting general and administrative expenses.

DaVita Clinical Research (DCR) will present 14 research abstracts at the American Society of Nephrology's Kidney Week from Oct. 22-25, 2020. This virtual event gathers over 13,000 kidney care professionals globally to discuss advancements in nephrology, particularly the impact of COVID-19 on dialysis patients. Key studies include topics on SARS-CoV-2 antibody tests in hemodialysis patients and racial disparities in kidney transplantation. DCR focuses on improving clinical outcomes through retrospective research and innovative practices in kidney care.